FIELD: medicine.
SUBSTANCE: invention concerns treating epilepsy. Disclosed is use of bicyclo[2.2.2]octane-2-carboxylate salt for reducing the number or intensity of seizures in a subject suffering from epilepsy, where the dose of the introduced bicyclo[2.2.2]octane-2-carboxylate salt ranges from 400 to 1200 mg a day. In the patients suffering alcohol dependence in the past, dysphoria and paroxysmal activity on the EEG disappeared or decreased as a result of the treatment, which correlated with the disappearance of alcohol dependence.
EFFECT: technical result consists in the implementation of the appointment, wherein the patient's health improved, the sleep and mood quality increased.
4 cl, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| [2,2,2]-BICYCLIC DERIVATIVES AND METHODS OF USING | 2009 |
|
RU2545876C2 |
| USE OF CARBAMATE DERIVATIVE FOR PREVENTION, RELIEF, OR TREATMENT OF MINOR EPILEPTIC SEIZURE OR EPILEPSY SHOWING MINOR EPILEPTIC SEIZURE | 2018 |
|
RU2787771C2 |
| TREATMENT OF FEAR OF PUBLIC SPEAKING WITH ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST | 2021 |
|
RU2840314C1 |
| USE OF PROBENECID FOR TREATMENT OF EPILEPTIC DISEASES, DISORDERS AND CONDITIONS | 2018 |
|
RU2785842C2 |
| TREATMENT USING ESLICARBAZEPINE ACETATE OR ESLICARBAZEPINE | 2012 |
|
RU2639120C2 |
| TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE-1 | 2003 |
|
RU2360910C2 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | 2016 |
|
RU2735277C2 |
| METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE | 2016 |
|
RU2740919C2 |
| NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USING | 2003 |
|
RU2323217C2 |
